Whitehawk Therapeutics Inc

NASDAQ:WHWK

Biotechnology

Healthcare
$3.13 +1.42%

+$0.06 today

Market cap
$184.70M
Beta
0.77
P/E (TTM)
-2.6
EPS (TTM)
-$1.67
52W Low $1.57High $5.50

Volume 0.28M

Average 0.31M

WHWK Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Whitehawk Therapeutics IncNASDAQ: WHWK

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income growth accelerates

Q4 FY2025 net income of $23.25M (cash outflow) rose 27.2% year over year, ahead of the -67.7% change in trailing-twelve-month net income. Sequentially, it rose 31.0% from the prior quarter. Over 3 fiscal years it compounded at -30.2% a year.

Context

  • Net income amounted to 288.3% of revenue in FY2025, up 43.1 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 9 analysts of -$57.94M (+181.3%) for the fiscal year ending Dec 2026, a step up from the -67.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$23.25M+31.0% QoQ
Last fiscal yearDec 2025
-$20.6M-67.7% YoY
LTMDec 2025
-$20.6M-67.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.2%-133.9%-161.1 pp
1 year-67.7%+181.3%+249.0 pp
3-year CAGR-30.2%+41.5%+71.7 pp
5-year CAGR+21.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(20.6M) USD
Year-over-year change
+67.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How WHWK compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -67.7% is the lowest of 9, against a peer median of +14.0%.
  • Net income amounts to 288.3% of revenue for WHWK, versus a peer median of 339.3%.
WHWK Competitors
Net Income for WHWK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$124.13M USD-44.6%-16.7%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$113.22M USD-48.4%+6.6%—
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
CNTXContext Therapeutics Inc.LTM Mar 2026$40.23M USD+45.6%+34.5%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$35.52M CAD+12.8%+16.7%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$34.98M USD+67.3%+52.9%—
CLNNClene Inc.LTM Mar 2026$33.51M USD+15.3%-4.4%25009.7%
OVIDOvid Therapeutics Inc.LTM Mar 2026$24.17M USD-3.2%-31.5%339.3%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$20.6M USD-67.7%-30.2%288.3%
Peer median (excluding WHWK) —+14.0%+1.1%339.3%

Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(110.09M)(60.51M)(65.77M)(63.69M)(20.6M)
Depreciation & Amortization105K159K169K193K79K
Deferred Income Tax00000
Stock-Based Compensation2.11M9.64M11.95M10.84M9.87M
Change in Working Capital3.96M(5.04M)(3.27M)3.72M1.93M
Accounts Receivables14.15M(1.86M)(3.63M)(415K)(1M)
Inventory0(1.86M)(3.27M)1.12M170K
Accounts Payables00003.92M
Other Working Capital(10.19M)(1.32M)3.62M3.02M(1.16M)
Other Non-Cash Items81.5M6.11M(2.75M)(10.61M)(78.77M)
Operating Cash Flow(22.42M)(49.64M)(59.66M)(59.55M)(97.43M)
Capital Expenditures(46K)(444K)(3.97M)(1.65M)(552K)
Acquisitions (Net)25.2M000101.29M
Purchases of Investments0(145.19M)(64.44M)(36.48M)(148.69M)
Sales of Investments012.75M151.62M63.34M59.85M
Other Investing Activities00000
Investing Cash Flow25.15M(132.89M)83.21M25.2M11.89M
Debt Repayment00000
Common Stock Issued155M72.5M0130K100M
Common Stock Repurchased00000
Dividends Paid(4.41M)0000
Other Financing Activities(8.78M)120K326K(16K)(5.63M)
Financing Cash Flow141.8M72.62M326K130K94.38M
Effect of Forex Changes000064K
Net Change in Cash144.53M(109.91M)23.87M(34.22M)8.9M
Free Cash Flow(22.47M)(50.08M)(63.64M)(61.2M)(97.99M)

Whitehawk Therapeutics Inc

NASDAQ:WHWK

Intrinsic Alpha fair value

Locked

Current Price

$3.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.